TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20015219

Group type: EXPERIMENTAL
Intervention: Intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Combination antiretroviral therapy (cART) only
Number of subjects: 54
Study: 17875076

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/day) for 20 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for 20 days
Number of subjects: 61
Study: 16132897

Group type: EXPERIMENTAL
Intervention: Parenteral lipid‐based nutrition (L group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard parenteral glucose‐based nutrition (G group)
Number of subjects: 33
Study: 12177267

Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous total hip arthroplasty
Number of subjects: 156

Group type: COMPARATOR
Intervention: Unilateral total hip arthroplasty
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cemented stem
Number of subjects: 156

Group type: COMPARATOR
Intervention: Cementless stem
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Bone-marrow-cell embolization
Number of subjects: 156
Study: 10464829

Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler 12 micrograms bd
Number of subjects: 469

Group type: COMPARATOR
Intervention: Salmeterol Accuhaler 50 micrograms bd
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler
Number of subjects: 469
Study: 7817481

Group type: EXPERIMENTAL
Intervention: Mitomycin C (43 weeks, range 3 to 90 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mitomycin C (during instillations)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Post-mitomycin C (after prophylaxis)
Number of subjects: 36
Study: 2112080

Group type: EXPERIMENTAL
Intervention: Hungarian-made levonorgestrel tablets (0.75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chinese-made levonorgestrel tablets (0.75 mg)
Number of subjects: 0
Study: 7323106

Group type: EXPERIMENTAL
Intervention: 360 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 720 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1080 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1440 mg intramuscular procaine penicillin daily for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 18
Study: 31426731

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 months
Number of subjects: 3127

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: Age >70 years
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3127
Study: 29079602

Group type: EXPERIMENTAL
Intervention: Peer-provided self-management intervention
Number of subjects: 440

Group type: COMPARATOR
Intervention: Treatment as usual supplemented by a booklet on self-management
Number of subjects: 440
Study: 26475266

Group type: EXPERIMENTAL
Intervention: TRK-100STP 120 μg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: TRK-100STP 240 μg/day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 23706123

Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21327422

Group type: EXPERIMENTAL
Intervention: Triflusal oral solution (600 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triflusal capsules (600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 19736358

Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducational psychotherapy plus treatment as usual
Number of subjects: 165

Group type: COMPARATOR
Intervention: Wait-list control (WLC) plus treatment as usual
Number of subjects: 165
Study: 20210680

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) combining C(max) and C(12h) after EC-MPS administration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: C(12h) after MMF ingestion
Number of subjects: 35
Study: 15565433

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (700 kcal/day deficit)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-CHO/normal-calorie diet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-CHO/low-calorie diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal-calorie diet (2,000-2,800 kcal/day)
Number of subjects: 17
Study: 11897543

Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10437612

Group type: EXPERIMENTAL
Intervention: Adjuvant intra-arterial chemotherapy (mitomycin C 8 mg/m2 on day 1 and 5-fluorouracil 800 mg/m2 on days 1-5 for four courses at 4-week intervals) in group A (14 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (group B, 16 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dukes A/B patients (12 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dukes C patients (30 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall probability of remaining free of recurrent disease
Number of subjects: 42
Study: 7777112

Group type: COMPARATOR
Intervention: Hypertensive uremic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normotensive uremic patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uremic patients (both hypertensive and normotensive)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study: 19256155

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (SB) 5.6 g/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lactitol (LA) 29 g/day
Number of subjects: 27
Study: 436049

Group type: EXPERIMENTAL
Intervention: Videotape educational program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 62
Study: 12734151

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) three times a day for two weeks before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo drug three times a day for two weeks before surgery
Number of subjects: 50
Study: 29737805

Group type: EXPERIMENTAL
Intervention: Probiotic supplement containing Lactobacillus acidophilus LA‐5, Bifidobacterium BB‐12, Streptococcus Thermophilus STY‐31, and Lactobacillus delbrueckii bulgaricus LBY‐27
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 64
Study: 27689551

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 minutes) + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Number of subjects: 26
Study: 24429175

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 22227576

Group type: EXPERIMENTAL
Intervention: CHESS plus therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Therapy only
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CHESS only
Number of subjects: 23
Study: 20357371

Group type: EXPERIMENTAL
Intervention: Insulin glargine 2.0 units/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine 1.5 units/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine 1.0 units/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine 0.5 units/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine (all doses)
Number of subjects: 20
Study: 17934975

Group type: EXPERIMENTAL
Intervention: 75 or 160 mg aspirin daily
Number of subjects: 289

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 289
Study: 16043735

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg OD) + Metformin (1.5-3.0 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo + Metformin (1.5-3.0 mg/day)
Number of subjects: 57
Study: 11796175

Group type: EXPERIMENTAL
Intervention: voglibose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 30
Study: 10048120

Group type: EXPERIMENTAL
Intervention: Ularitide (U5, U20, U40, U80 ng/kg/min)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (U0)
Number of subjects: 176
Study: 7484129

Group type: EXPERIMENTAL
Intervention: Operation and walking-cast for 5 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Walking-cast alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 79
Study: 2378290

Group type: EXPERIMENTAL
Intervention: Neuropsychological performance index (alcoholics who resumed drinking)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Neuropsychological performance index (abstainers)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Neuropsychological performance index (nonalcoholics)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Depressive symptoms, ADD, and performance index
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Retest performance (all groups)
Number of subjects: 103
Study: 312709

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 121
Study: 31179546

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (three doses: 0, 2, 6 months)
Number of subjects: 0
Study: 30557108

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy (ESWT) with standard care
Number of subjects: 336

Group type: COMPARATOR
Intervention: Sham treatment with standard care
Number of subjects: 336
Study: 26935044

Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg orally for the first 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22497849

Group type: EXPERIMENTAL
Intervention: Spirulina
Number of subjects: 66

Group type: COMPARATOR
Intervention: Silymarin
Number of subjects: 66
Study: 20580827

Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 17908974

Group type: EXPERIMENTAL
Intervention: docetaxel + imatinib
Number of subjects: 144

Group type: COMPARATOR
Intervention: docetaxel + placebo
Number of subjects: 144
Study: 15763039

Group type: EXPERIMENTAL
Intervention: Supplementing written trial information with an explanation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Description of a treatment as new
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Doctor's uncertainty about the best treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Random allocation suggestion by a doctor
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Justification for random allocation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active processing of trial information
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Current best practice in trial information
Number of subjects: 9
Study: 11426168

Group type: EXPERIMENTAL
Intervention: 4 degrees wedged cages
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rectangular cages
Number of subjects: 40
Study: 9713140

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg, single dose)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8276209

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2659288

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 157

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Beta-lactam-aminoglycoside combination
Number of subjects: 157
Study: 31505665

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (2 × 10^7 pfu)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (1 × 10^8 pfu)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (all groups)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study: 28780550

Group type: EXPERIMENTAL
Intervention: Four-stage, multifaceted organisational intervention including data reviews, education, and facilitated action planning.
Number of subjects: 1289
Study: 26291917

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anal sphincter exercises with biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (educational pamphlet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24176804

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy‐cognitive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written accounts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre‐treatment AS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre‐treatment AS dimensions
Number of subjects: 0
Study: 21613029

Group type: EXPERIMENTAL
Intervention: Cervical barrier (2 mm obturation removed)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical barrier (3 mm obturation removed)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gutta‐percha only (positive control)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Completely impermeabilized (negative control)
Number of subjects: 70
Study: 19453313

Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (2.5 mg)
Number of subjects: 40
Study: 16685054

Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg/d)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 15513235

Group type: EXPERIMENTAL
Intervention: Warning signals contingent with the reaction stimuli
Number of subjects: 68

Group type: COMPARATOR
Intervention: Erratic and irrelevant signals
Number of subjects: 68
Study: 11321641

Group type: EXPERIMENTAL
Intervention: Affective orienting task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-affective orienting task
Number of subjects: 0
Study: 9625272

Group type: EXPERIMENTAL
Intervention: 200 mg [14C]-labelled Losigamone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 mg of each of the unlabelled enantiomers
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Losigamone
Number of subjects: 5
Study: 7519696

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (verapamil and diltiazem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation dihydropyridines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium-channel blockers
Number of subjects: 0
Study: 3261159

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 100
Study: 29322504

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted group
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 218
Study: 28889167

Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention (45-minute interactive instructor-led session and 45-minute audio session)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention
Number of subjects: 25
Study: 25578351

Group type: EXPERIMENTAL
Intervention: Holmium laser lithotripsy (LL)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy (PL)
Number of subjects: 982
Study: 24298801

Group type: EXPERIMENTAL
Intervention: Modified single length technique with Mtwo instrument (Group M)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Modified step‐back technique with Gates‐Glidden bur (Group G)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Step‐back technique with stainless steel H‐files (Group H)
Number of subjects: 265
Study: 21164018

Group type: EXPERIMENTAL
Intervention: 4-variable MDRD equation (4V-MDRDE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-variable MDRD equation (6V-MDRDE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDRD equations (4V-MDRDE and 6V-MDRDE)
Number of subjects: 0
Study: 18804142

Group type: EXPERIMENTAL
Intervention: Formulation F4 (combination of vitamins A, C, E and SCE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formulation F1 (vehicle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation F3 (SCE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation F4 (combination of vitamins and SCE)
Number of subjects: 0
Study: 17063290

Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open retro-rectus mesh repair
Number of subjects: 66
Study: 12170407

Group type: EXPERIMENTAL
Intervention: Refeeding 4 hours after ES
Number of subjects: 146

Group type: COMPARATOR
Intervention: Refeeding 24 hours after ES
Number of subjects: 146
Study: 10436310

Group type: EXPERIMENTAL
Intervention: Low-dose n-3 fatty acids (330 mg/day docosahexaenoic acid and 630 mg/day eicosapentanoic acid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 18
Study: 7788823

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (OND) 0.1 mg.kg-1
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (OND)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 233
Study: 2177861

Group type: EXPERIMENTAL
Intervention: Fragmin 2500 UI anti‐Xa once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 UI twice daily
Number of subjects: 40
Study: 378313

Group type: EXPERIMENTAL
Intervention: Brush cytology before biopsy
Number of subjects: 324

Group type: COMPARATOR
Intervention: Biopsy alone
Number of subjects: 324

Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 324
Study: 6621809

Group type: EXPERIMENTAL
Intervention: Compensatory vestibular‐proprioceptive stimulation provided by waterbed flotation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 30850023

Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 480

Group type: COMPARATOR
Intervention: Deferred stenting (scheduled 4-10 days after primary angioplasty)
Number of subjects: 480
Study: 30470853

Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (PMX)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 194
Study: 26672127

Group type: EXPERIMENTAL
Intervention: meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5)
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: meloxicam and placebo
Number of subjects: 37
Study: 25232839

Group type: EXPERIMENTAL
Intervention: 1200 IU/d cholecalciferol
Number of subjects: 137

Group type: COMPARATOR
Intervention: 400 IU/d cholecalciferol (control)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both groups (1200 IU/d and 400 IU/d)
Number of subjects: 137
Study: 23171610

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HIAT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CAT
Number of subjects: 10
Study: 20187899

Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino fruit acid (AFA) peels
Number of subjects: 0
Study: 17585872

Group type: EXPERIMENTAL
Intervention: Video intervention prior to forensic medical examination
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 140
Study: 15653010

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 80 mg twice daily for 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 12184902

Group type: EXPERIMENTAL
Intervention: Ultrasonic (US) operative technique
Number of subjects: 59

Group type: COMPARATOR
Intervention: Electrosurgery (ELC) operative technique
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 59

Group type: COMPARATOR
Intervention: Electrosurgery (ELC)
Number of subjects: 59
Study: 10660871

Group type: EXPERIMENTAL
Intervention: Maltodextrin (CHO) at a dosage of 0.7 g.kg body mass‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 6
Study: 7607967

Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 115
Study: 2220651

Group type: EXPERIMENTAL
Intervention: Acebutolol (n = 124)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo (n = 221)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Chlorthalidone (n = 125)
Number of subjects: 847
Study: 341998

Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30898826

Group type: EXPERIMENTAL
Intervention: Standardised public health approach to strengthen the management of LTBI, including contact measurement registries and regular in-service LTBI management training.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual LTBI care with no explicit evaluation, strengthening or training activities.
Number of subjects: 24
Study: 27624505

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 59
Study: 25469738

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA) using a 3.5‐mm open‐irrigated‐tip (OIT) catheter with contact force measurement capabilities
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard OIT catheters
Number of subjects: 99
Study: 23383037

Group type: EXPERIMENTAL
Intervention: Oral 300 mg tenofovir disoproxil fumarate
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Vaginal 1% tenofovir gel (40 mg)
Number of subjects: 144